MDXG: Mimedx Group Inc Company Profile & Statistics

About

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.

Info & Links

CEO

Joseph H. Capper

Headquarters

1775 W OAK COMMONS COURT, NE
MARIETTA, GA 30062, UNITED STATES

Auditor

BDO USA, LLP

Share holders

810

Employees

895

Mimedx Group Inc Statistics

Valuation Measures

Market Capitalization²

1.36B

Enterprise Value

1.29B

Enterprise Value/EBITDA(ttm)

19.15

Price to Earnings Ratio(ttm)

35.23

Price to Sales(ttm)

3.93

Price to Book(mrq)

7.44

Price to Cash(ytd)

48.71

Profitability

Gross Margin(ttm)

83.37%

Operating Margin(ttm)

12.38%

Profit Margin(ttm)

23.25%

Return on Equity(ttm)

26.21%

Return on Invested Capital(ttm)

45.50%

Return on Assets(ttm)

18.15%

Income Statement

Revenue(ttm)

342.81M

Revenue Per Share(ttm)

2.33

Gross Profit(ttm)

285.80M

EBITDA(ttm)³

67.51M

Net Income Available to Common(ttm)

80.32M

Diluted EPS(ttm)

0.55

Share Statistics

Beta (5Y Monthly)

1.98

52-Week Change

16.02%

S&P 500 52-Week Change

25.75%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

146.95M

Dividend Yield

0.00%

Float⁴

145.04M

% Held by Insiders

1.30%

% Held by Institutions

79.15%

Balance Sheet

Total Cash(mrq)

88.80M

Total Cash Per Share(mrq)

0.60

Total Debt(mrq)

19.02M

Total Debt/Equity(mrq)

10.51%

Current Ratio(mrq)

4.10%

Quick Ratio(mrq)

3.53%

Book Value Per Share(mrq)

1.23

Cash Flow

Operating Cash Flow Per Share(ytd)

0.32

Free Cash Flow(ytd)

46.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MDXG

Mimedx Group Inc

Mimedx Group Inc Profile